@article{82c73aa84ed445548dcec580da6b70ab,
title = "PET staging of amyloidosis using striatum",
abstract = "Introduction: Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical; high cortical, low striatal; and high cortical, high striatal amyloid; hypothesizing this model could better reflect Alzheimer's dementia progression than a model based only on cortical measures. Methods: We classified PET data from 1433 participants (646 normal, 574 mild cognitive impairment, and 213 AD), explored the successive involvement of cortex and striatum using 3-year follow-up PET data, and evaluated the associations between PET stages, hippocampal volumes, and cognition. Results: Follow-up data indicated that PET detects amyloid first in cortex and then in striatum. Our three-category staging including striatum better predicted hippocampal volumes and subsequent cognition than a three-category staging including only cortical amyloid. Discussion: PET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research.",
keywords = "Alzheimer's disease, Amyloid PET imaging, Classification, Cognitive aging, Cortex, MCI, Staging, Striatum, Structural MRI",
author = "{Alzheimer's Disease Neuroimaging Initiative} and {Harvard Aging Brain Study} and Hanseeuw, {Bernard J.} and Betensky, {Rebecca A.} and Mormino, {Elizabeth C.} and Schultz, {Aaron P.} and Jorge Sepulcre and Becker, {John A.} and Jacobs, {Heidi I.L.} and Buckley, {Rachel F.} and LaPoint, {Molly R.} and Patrizia Vannini and Donovan, {Nancy J.} and Chhatwal, {Jasmeer P.} and Marshall, {Gad A.} and Papp, {Kathryn V.} and Amariglio, {Rebecca E.} and Rentz, {Dorene M.} and Sperling, {Reisa A.} and Johnson, {Keith A.}",
note = "Funding Information: The authors thank Michel J. Grothe for his help during the reviewing process of this manuscript. ADNI (NIH Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) contributed to the data collection for this study. ADNI is funded by the National Institute on Aging NIH/NIA) and the National Institute of Biomedical Imaging and Bioengineering and also through generous contributions from AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate Ltd.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euroimmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research and Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of Southern California. The NIH/NIA Grant P01AG036694 funds the HABS, and the R01AG046396 funds the HABS tau-PET data. Besides, K.A.J. receives funding from the Alzheimer's Association, Harvard NeuroDiscovery Center, and Fidelity Biosciences. B.J.H. receives funding from the Belgian National Science Foundation (FNRS grant SPD28094292) and the Belgian Foundation for Alzheimer Research (SAO-FRA grant P16008). These funding sources had no influence on study analyses or manuscript writing. Funding Information: The authors thank Michel J. Grothe for his help during the reviewing process of this manuscript. ADNI (NIH Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) contributed to the data collection for this study. ADNI is funded by the National Institute on Aging NIH/NIA) and the National Institute of Biomedical Imaging and Bioengineering and also through generous contributions from AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate Ltd.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euroimmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research and Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of Southern California. Funding Information: The NIH/NIA Grant P01AG036694 funds the HABS, and the R01AG046396 funds the HABS tau-PET data. Besides, K.A.J. receives funding from the Alzheimer's Association, Harvard NeuroDiscovery Center, and Fidelity Biosciences. B.J.H. receives funding from the Belgian National Science Foundation (FNRS grant SPD28094292) and the Belgian Foundation for Alzheimer Research (SAO-FRA grant P16008). Publisher Copyright: {\textcopyright} 2018 The Authors Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2018",
month = oct,
doi = "10.1016/j.jalz.2018.04.011",
language = "English (US)",
volume = "14",
pages = "1281--1292",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "10",
}